Subscribe to Search results

The wording of the warning label on Armour's Factorate was done in a roundabout way; unlike the more direct approach of some other manufacturers such as Cutter, Armour's said that "Despite careful selection of donors, it may contain causative agents of viral hepatitis."

Published on:

The warning label on Armour's Factorate package continued to state that the risk of transmitting viral hepatitis to patients was still present, and personnel administering this should exercise caution.

Published on:

David Gury at Alpha sent out a series of urgent communications on AIDS on their new donor selection policies which were due to be be given to donors, deferred donors and donor centre personnel.

Published on:

Dr Lane submitted a draft proof of evidence for the HIV Haemophilia Litigation.

Published on:

Dr Lane focused on the view that BPL should be rebuilt. A large investment was required.

Published on:

The Expert Group on the Treatment of Haemophilia had set a goal of 250,000 donations to be used for Factor 8 concentrate (March 1973); this had been increased to 275,000 by regional transfusion directors following the Joint Steering Committee (June and July 1973).

Published on:

Dr Bowley wrote a letter to colleagues seeking to make a case for using better quality cryoprecipitate instead of imported factor concentrates.

Published on:

Dr Biggs wrote to Dr Waiter discussing seeking an increase in the supplies of commercially produced concentrates.

Published on:

By 1976, 46% of donations in Scotland were issued as red cell concentrates. By 1982, 60% of donations were being processed into red cell concentrates with 200ml of plasma removed.

Published on:

A Working Party on Human AHG meeting debated where the preparation of AHG should take place.

Published on:

Ministers continued to stress the need for collaboration between Scotland and England in manufacturing blood products.

Published on:

A NBTS meeting was held when it became apparent that any further plasma provided to BPL for fractionation would have to be dealt with in "unsatisfactory accommodation".

Published on:

R Smart published a report titled "Blood Products Laboratory: Redevelopment".

Published on:

At a meeting of the Scientific and Technical Committee for the Central Blood Laboratories, members did not support commercial development, and recommended that no time should be lost in planning for a completely new NHS plant.

Published on:

Ministers decided to defer the eventual decision on whether to build a new laboratory within the NHS until other possibilities had been investigated.

Published on:

Dr Lane was authorised to proceed with the stop-gap project. The DHSS anticipated that the sum of £750,000 would be available for the capital development of BPL in 1980/1981.

Published on:

It was not until this time that Dr Lane was given formal authority to proceed to tender with MARP01, the name given to the stop-gap proposal.

Published on:

Dr Gunson tabled a paper concluding that the number of plasmapheresis facilities should be increased. The Advisory Committee of the NBTS agreed to set up a Working Party and liaise with Scotland.

Published on:

The Working Party to Advise on Plasma Supplies for Self-Sufficiency in Blood Products published a preliminary report estimating costs of plasmapheresis compared favourably with the estimated cost of obtaining the same weight of whole blood.

Published on:

A Policy Steering Group for the Redevelopment of BPL meeting was held.

Published on: